Ekaterina Savinova
Ekaterina Savinova has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- A. N. Kovalskaya
Samara State Medical University
5 shared publications - Dmitriy Viktorovich Duplyakov
FSBEI HE «Samara State Medical University» of the Ministry of Healthcare of the Russian Federation; SBHI «V. P. Polyakov Samara Regional Clinical Cardiology Dispensary
5 shared publications - G. R. Bikbaeva
Samara State Medical University; Polyakov Samara Regional Clinical Cardiology Dispensary
5 shared publications - Polina D. Duplyakova
Polyakov Samara Regional Clinical Cardiology Dispensary
4 shared publications - A. A. Tukhbatova
Samara State Medical University; Polyakov Samara Regional Clinical Cardiology Dispensary
3 shared publications - E. M. Sukhinina
Polyakov Samara Regional Clinical Cardiology Dispensary
3 shared publications
Latest Publications
- Open Access
- 4 October 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (9) , 6821
Impact of long-term combination lipid-lowering therapy on plaque vulnerability in patients with acute coronary syndrome
Aim. To evaluate the potential of high-dose combination lipid-lowering therapy (LLT) in reducing coronary atherosclerosis in patients after acute coronary syndrome (ACS), depending on the presence of vulnerable plaques (VPs). Material and methods . The study included 125 patients (men, 68%; mean age, 56,9±9,8 years) after ACS and percutaneous coronary intervention. After one month of treatment, coronary computed tomography angiography (CCTA) was performed, and the patients were randomized into two groups depending on VP presence. After 12 months, a repeat CCTA was performed during LLT. Results. Combined LLT resulted in a significant decrease in VP criteria as follows: Me (Q 1 ;Q 3 ), 2 (1;4) vs 2 (1;2), p=0,002. In the group of patients with VP, the prevalence of atherosclerosis in the following coronary arteries was significantly reduced: the left main coronary artery (p=0,008), the left anterior descending artery (p=0,002), and the circumflex artery (p=0,016). A significant decrease in the SSS and SIS scales was also noted between visits 2 and 6 in the group with VP — Me (Q 1 ;Q 3 ), 3 (1;4) vs 2 (1;4), p1 ;Q 3 ), 35 (1;138) vs 111 (29;247), p=0,004, and at visit 6: Me (Q 1 ;Q 3 ), 35 (0;178) vs 105 (31;245), p=0,008. After 1-year therapy, a significant decrease in the level of total cholesterol (pConclusion . Combined LLT after ACS leads to a significant reduction in the severity of coronary atherosclerosis, as measured by CCTA and SIS and SSS scales, due to VP stabilization.
- 4 October 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (9) , 6821
Open AccessImpact of long-term combination lipid-lowering therapy on plaque vulnerability in patients with acute coronary syndrome
Aim. To evaluate the potential of high-dose combination lipid-lowering therapy (LLT) in reducing coronary atherosclerosis in patients after acute coronary syndrome (ACS), depending on the presence of vulnerable plaques (VPs). Material and methods . The study included 125 patients (men, 68%; mean age, 56,9±9,8 years) after ACS and percutaneous coronary intervention. After one month of treatment, coronary computed tomography angiography (CCTA) was performed, and the patients were randomized into two groups depending on VP presence. After 12 months, a repeat CCTA was performed during LLT. Results. Combined LLT resulted in a significant decrease in VP criteria as follows: Me (Q 1 ;Q 3 ), 2 (1;4) vs 2 (1;2), p=0,002. In the group of patients with VP, the prevalence of atherosclerosis in the following coronary arteries was significantly reduced: the left main coronary artery (p=0,008), the left anterior descending artery (p=0,002), and the circumflex artery (p=0,016). A significant decrease in the SSS and SIS scales was also noted between visits 2 and 6 in the group with VP — Me (Q 1 ;Q 3 ), 3 (1;4) vs 2 (1;4), p1 ;Q 3 ), 35 (1;138) vs 111 (29;247), p=0,004, and at visit 6: Me (Q 1 ;Q 3 ), 35 (0;178) vs 105 (31;245), p=0,008. After 1-year therapy, a significant decrease in the level of total cholesterol (pConclusion . Combined LLT after ACS leads to a significant reduction in the severity of coronary atherosclerosis, as measured by CCTA and SIS and SSS scales, due to VP stabilization.
- Open Access
- 29 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7564
Ezetimibe Versus Alirocumab and Plaque Vulnerability in Patients with Acute Coronary Syndrome Not Achieving LDL-Cholesterol Target with Statin Therapy: The COMBI-LLT-ACS Randomized Trial
Objective: To compare two lipid-lowering therapy strategies involving Ezetimibe and Alirocumab on the vulnerability of atherosclerotic plaque (AP) in patients with acute coronary syndrome (ACS) not achieving the LDL-cholesterol target while on intensive statin therapy. Methods: Combi-LLT-ACS (Patients receiving combination lipid-lowering therapy admitted with the acute coronary syndrome) included 125 patients aged 59 (51; 64) years, of whom 67.2% were men. All underwent percutaneous coronary intervention of the IRA; also, all patients had at least one stenosis < 50% in non-IRA, had high compliance with statins, and did not reached LDL-C level of ≤1.4 mmol/L. Patients underwent Coronary Computed Tomography Angiography (CCTA) to detect vulnerable AP as well as lipid profile and numerous biomarkers: neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), monocyte to high-density lipoprotein ratio (MHR), systemic inflammatory response index (SIRI), matrix metalloprotease type 9 (MMP-9), tissue inhibitor of metalloproteinases type 1 (TIMP-1), Galectin-3 (GAL-3), neutrophil gelatinase-associated lipocalin (NGAL), and C-reactive protein (CRP). Thereafter, they were randomized into two groups, Ezetimibe vs. Alirocumab, on the same visit. The follow-up period was 52 weeks. We used the following CCTA criteria to detect vulnerable AP: positive remodeling, napkin-ring sign, spotty calcification, and low-attenuation plaque. Results: One month after ACS, vulnerable APs were observed by CCTA in 56 patients (44.8%). After 52 weeks, 10 (17.9%) patients showed stabilization of previously vulnerable APs or a decrease in the number of AP vulnerability criteria. At week 52, TC and LDL-C levels decreased significantly over time in both groups. Both arms of therapy demonstrated a positive effect on the inflammatory markers and markers of extracellular matrix remodeling. Direct comparison of changes between groups revealed no statistically significant differences in the number of vulnerability criteria (p = 0.930); however, in the group receiving Ezetimibe, we found a statistically significant change over the observation period (p = 0.032). Conclusions: Among patients with ACS, receiving a high-intensity statin in combination with Ezetimibe or Alirocumab prevented the emergence of new vulnerable coronary lesions over 52 weeks. While direct regression of specific vulnerability criteria was not observed, these therapeutic strategies were associated with a reduction in LDL-C and biomarkers of inflammation and extracellular matrix remodeling.
- 29 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7564
Open AccessEzetimibe Versus Alirocumab and Plaque Vulnerability in Patients with Acute Coronary Syndrome Not Achieving LDL-Cholesterol Target with Statin Therapy: The COMBI-LLT-ACS Randomized Trial
Objective: To compare two lipid-lowering therapy strategies involving Ezetimibe and Alirocumab on the vulnerability of atherosclerotic plaque (AP) in patients with acute coronary syndrome (ACS) not achieving the LDL-cholesterol target while on intensive statin therapy. Methods: Combi-LLT-ACS (Patients receiving combination lipid-lowering therapy admitted with the acute coronary syndrome) included 125 patients aged 59 (51; 64) years, of whom 67.2% were men. All underwent percutaneous coronary intervention of the IRA; also, all patients had at least one stenosis < 50% in non-IRA, had high compliance with statins, and did not reached LDL-C level of ≤1.4 mmol/L. Patients underwent Coronary Computed Tomography Angiography (CCTA) to detect vulnerable AP as well as lipid profile and numerous biomarkers: neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), monocyte to high-density lipoprotein ratio (MHR), systemic inflammatory response index (SIRI), matrix metalloprotease type 9 (MMP-9), tissue inhibitor of metalloproteinases type 1 (TIMP-1), Galectin-3 (GAL-3), neutrophil gelatinase-associated lipocalin (NGAL), and C-reactive protein (CRP). Thereafter, they were randomized into two groups, Ezetimibe vs. Alirocumab, on the same visit. The follow-up period was 52 weeks. We used the following CCTA criteria to detect vulnerable AP: positive remodeling, napkin-ring sign, spotty calcification, and low-attenuation plaque. Results: One month after ACS, vulnerable APs were observed by CCTA in 56 patients (44.8%). After 52 weeks, 10 (17.9%) patients showed stabilization of previously vulnerable APs or a decrease in the number of AP vulnerability criteria. At week 52, TC and LDL-C levels decreased significantly over time in both groups. Both arms of therapy demonstrated a positive effect on the inflammatory markers and markers of extracellular matrix remodeling. Direct comparison of changes between groups revealed no statistically significant differences in the number of vulnerability criteria (p = 0.930); however, in the group receiving Ezetimibe, we found a statistically significant change over the observation period (p = 0.032). Conclusions: Among patients with ACS, receiving a high-intensity statin in combination with Ezetimibe or Alirocumab prevented the emergence of new vulnerable coronary lesions over 52 weeks. While direct regression of specific vulnerability criteria was not observed, these therapeutic strategies were associated with a reduction in LDL-C and biomarkers of inflammation and extracellular matrix remodeling.
- 15 July 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (5)
Vulnerable plaques and lipid changes over statin therapy in patients with acute coronary syndrome. Initial data from the Combi-LLT ACS trial
Aim. To assess the detection rate of vulnerable plaques using computed tomography (CT) in patients after acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). Material and methods. The study included 125 patients with ACS who underwent PCI (men, 68%; median age, 59 (51-66) years). One month after the index event, patients who did not achieve target low-density lipoprotein cholesterol values were divided into two groups depending on the signs of vulnerable plaques according to CT data. Results. Vulnerable plaques were detected in 56 (44,8%) patients using CT (69,6% men, median age 60 (51-63) years). Patients with vulnerable plaques were more likely to have right coronary artery (CA) involvement — 53,6 vs 11,6% (pConclusion. The detection rate of vulnerable plaques in patients after ACS and PCI not achieved target LDL values while receiving highdose statin therapy was 44,8%. Patients with vulnerable plaques were characterized by more spread atherosclerotic coronary involvement and a high calcium index.
- 15 July 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (5)
Vulnerable plaques and lipid changes over statin therapy in patients with acute coronary syndrome. Initial data from the Combi-LLT ACS trial
Aim. To assess the detection rate of vulnerable plaques using computed tomography (CT) in patients after acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). Material and methods. The study included 125 patients with ACS who underwent PCI (men, 68%; median age, 59 (51-66) years). One month after the index event, patients who did not achieve target low-density lipoprotein cholesterol values were divided into two groups depending on the signs of vulnerable plaques according to CT data. Results. Vulnerable plaques were detected in 56 (44,8%) patients using CT (69,6% men, median age 60 (51-63) years). Patients with vulnerable plaques were more likely to have right coronary artery (CA) involvement — 53,6 vs 11,6% (pConclusion. The detection rate of vulnerable plaques in patients after ACS and PCI not achieved target LDL values while receiving highdose statin therapy was 44,8%. Patients with vulnerable plaques were characterized by more spread atherosclerotic coronary involvement and a high calcium index.
- Open Access
- 15 July 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (5) , 4318
Vulnerable plaques and lipid changes over statin therapy in patients with acute coronary syndrome. Initial data from the Combi-LLT ACS trial
Aim. To assess the detection rate of vulnerable plaques using computed tomography (CT) in patients after acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI).Material and methods. The study included 125 patients with ACS who underwent PCI (men, 68%; median age, 59 (51-66) years). One month after the index event, patients who did not achieve target low-density lipoprotein cholesterol values were divided into two groups depending on the signs of vulnerable plaques according to CT data.Results. Vulnerable plaques were detected in 56 (44,8%) patients using CT (69,6% men, median age 60 (51-63) years). Patients with vulnerable plaques were more likely to have right coronary artery (CA) involvement — 53,6 vs 11,6% (pConclusion. The detection rate of vulnerable plaques in patients after ACS and PCI not achieved target LDL values while receiving highdose statin therapy was 44,8%. Patients with vulnerable plaques were characterized by more spread atherosclerotic coronary involvement and a high calcium index.
- 15 July 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (5) , 4318
Open AccessVulnerable plaques and lipid changes over statin therapy in patients with acute coronary syndrome. Initial data from the Combi-LLT ACS trial
Aim. To assess the detection rate of vulnerable plaques using computed tomography (CT) in patients after acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI).Material and methods. The study included 125 patients with ACS who underwent PCI (men, 68%; median age, 59 (51-66) years). One month after the index event, patients who did not achieve target low-density lipoprotein cholesterol values were divided into two groups depending on the signs of vulnerable plaques according to CT data.Results. Vulnerable plaques were detected in 56 (44,8%) patients using CT (69,6% men, median age 60 (51-63) years). Patients with vulnerable plaques were more likely to have right coronary artery (CA) involvement — 53,6 vs 11,6% (pConclusion. The detection rate of vulnerable plaques in patients after ACS and PCI not achieved target LDL values while receiving highdose statin therapy was 44,8%. Patients with vulnerable plaques were characterized by more spread atherosclerotic coronary involvement and a high calcium index.
- Open Access
- 19 September 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (1) , 5850
Features of simple inflammation markers in assessing the plaque vulnerability in patients with acute coronary syndrome
Aim. To assess the relationship between simple inflammation markers and plaque vulnerability criteria according to coronary computed tomography angiography (CCTA), as well as lipid profile parameters in patients with acute coronary syndrome (ACS).Material and methods. This prospective, randomized, single-center study included 125 patients admitted urgently with the clinical performance of ACS (myocardial infarction (MI) — 94 patients; unstable angina (UA) — 31). All patients underwent percutaneous coronary intervention of the infarct-related artery. In addition, all patients had atherosclerotic plaques with stenosis Results. Of the 125 patients included in the study, MI was diagnosed in 94 (75%) patients, and UA in the remaining cases. In the acute period, in patients with MI, the HDL-C value was significantly lower 1,2 (1,03; 1,5) mmol/L than in the group of patients with UA (1,4 (1,24; 1,58) mmol/L), p=0,044. NLR was higher in patients with MI — 2,96 (2,09; 3,99) versus 2,21 (1,69; 2,71) in the UA group (p=0,018). One month after the index event, the HDL-C level remained significantly lower in the MI group 1,08 (0,95; 1,34) mmol/L, and the MHR was higher (0,52 (0,37; 0,64)) than in UA (1,25 (1,15; 1,34) mmol/L and 0,41 (0,31; 0,52)), respectively. The LCR after 1 month was almost 2 times higher in the UA group — 1,32 (0,65; 2,28) versus 0,66 (0,34; 1,28) in the MI group (p=0,028). The vulnerability criteria of plaques according to CCTA data were identified in 55 (44%) patients in the general group with ACS, of which positive remodeling was detected in 35 patients, a low-density area — in 30, and punctate calcifications (PC) — in 11. Patients in the general ACS group were divided by vulnerability criteria. Patients with PC had a significantly (p=0,004) higher level of HDL-C 1,22 (1,02; 1,34), compared to those without it 0,97 (0,77; 1,13). The MHR was higher (p=0,024) in the presence of PC (0,61 (0,48; 0,86)) than without it (0,46 (0,35; 0,63)). No significant differences were found for other indicators. When conducting the ROC analysis in patients with PC, the threshold level of HDL-C was 0,98 (AUC: 0,76, Sensitivity 66,7%, Specificity 77,4%), the threshold level of HDL-C in the presence of low-density area simultaneously with PC was also 0,98 (AUC: 0,83, Sensitivity 75%, Specificity 75,7%).Conclusion. The HDL-C and MHR indicators significantly changed in patients who had ACS and microcalcifications in the plaques.
- 19 September 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (1) , 5850
Open AccessFeatures of simple inflammation markers in assessing the plaque vulnerability in patients with acute coronary syndrome
Aim. To assess the relationship between simple inflammation markers and plaque vulnerability criteria according to coronary computed tomography angiography (CCTA), as well as lipid profile parameters in patients with acute coronary syndrome (ACS).Material and methods. This prospective, randomized, single-center study included 125 patients admitted urgently with the clinical performance of ACS (myocardial infarction (MI) — 94 patients; unstable angina (UA) — 31). All patients underwent percutaneous coronary intervention of the infarct-related artery. In addition, all patients had atherosclerotic plaques with stenosis Results. Of the 125 patients included in the study, MI was diagnosed in 94 (75%) patients, and UA in the remaining cases. In the acute period, in patients with MI, the HDL-C value was significantly lower 1,2 (1,03; 1,5) mmol/L than in the group of patients with UA (1,4 (1,24; 1,58) mmol/L), p=0,044. NLR was higher in patients with MI — 2,96 (2,09; 3,99) versus 2,21 (1,69; 2,71) in the UA group (p=0,018). One month after the index event, the HDL-C level remained significantly lower in the MI group 1,08 (0,95; 1,34) mmol/L, and the MHR was higher (0,52 (0,37; 0,64)) than in UA (1,25 (1,15; 1,34) mmol/L and 0,41 (0,31; 0,52)), respectively. The LCR after 1 month was almost 2 times higher in the UA group — 1,32 (0,65; 2,28) versus 0,66 (0,34; 1,28) in the MI group (p=0,028). The vulnerability criteria of plaques according to CCTA data were identified in 55 (44%) patients in the general group with ACS, of which positive remodeling was detected in 35 patients, a low-density area — in 30, and punctate calcifications (PC) — in 11. Patients in the general ACS group were divided by vulnerability criteria. Patients with PC had a significantly (p=0,004) higher level of HDL-C 1,22 (1,02; 1,34), compared to those without it 0,97 (0,77; 1,13). The MHR was higher (p=0,024) in the presence of PC (0,61 (0,48; 0,86)) than without it (0,46 (0,35; 0,63)). No significant differences were found for other indicators. When conducting the ROC analysis in patients with PC, the threshold level of HDL-C was 0,98 (AUC: 0,76, Sensitivity 66,7%, Specificity 77,4%), the threshold level of HDL-C in the presence of low-density area simultaneously with PC was also 0,98 (AUC: 0,83, Sensitivity 75%, Specificity 75,7%).Conclusion. The HDL-C and MHR indicators significantly changed in patients who had ACS and microcalcifications in the plaques.